Proteostasis Therapeutics Inc
Change company Symbol lookup
Select an option...
PTI Proteostasis Therapeutics Inc
CALB California BanCorp
$NOPM2 Refinitiv Norway Metal & Mining Inde
EBAY eBay Inc
PTON Peloton Interactive Inc
GO Grocery Outlet Holding Corp
NUE Nucor Corp
SJM J M Smucker Co
KR Kroger Co
HON Honeywell International Inc

Health Care : Biotechnology | Small Cap Value
Company profile

Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of novel therapeutics to treat cystic fibrosis (CF), and other diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. The Company focuses on identifying therapies that restore protein function. The Company’s CF focused pipeline consists of novel CFTR modulators including correctors, potentiators and amplifiers. The Company’s clinical developments include PTI-801, a third generation CFTR corrector, PTI-808, a CFTR potentiator, and PTI-428, a CFTR amplifier.


Last Trade
0.03 (2.97%)
B/A Size

Market Hours

Closing Price
Day's Change
-0.01 (-0.98%)
Bid close
Ask close
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Hormel shares up premarket after earnings top estimates

6:47 am ET August 25, 2020 (MarketWatch)

Hormel Foods Corp. shares (HRL) rose 1.6% in premarket trade Tuesday, after the parent of food brands, including Skippy peanut butter, Spam and Applegate posted better-than-expected earnings for its fiscal third quarter. Hormel said it had net income of $203.1 million, or 37 cents a share, in the quarter to July 26, compared with income of $199.4 million, or 37 cents a share, in the year-earlier period. Sales rose to $2.381 billion from $2.291 billion. The FactSet consensus was for EPS of 34 cents and sales of $2.366 billion. Chief Executive Jim Snee said the company saw strength across its retail and deli businesses, along with a rebound in its foodservice business. "We expect the fourth quarter to mirror many of the dynamics we saw in the third quarter," Snee said. "However, the magnitude of additional recovery in the foodservice industry, the performance of the entire food supply chain and the state of the broader economy remain highly uncertain." The company absorbed about $40 million in supply chain costs related to lower production volumes, employee bonuses and enhanced safety measures at its production facilities. "On a year-to-date basis, total incremental costs were $60 million, and the range of incremental costs in the fourth quarter is $20-$40 million. The total incremental supply chain costs are anticipated to be $80-$100 million in fiscal 2020," it said in a statement. Shares have gained 17% in the year to date, while the S&P 500 has gained 6%.

-Ciara Linnane; 415-439-6400;

(END) Dow Jones Newswires

August 25, 2020 06:47 ET (10:47 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.